Mutated lung cancer responds to targeted therapy
Among patients with advanced unresectable cancer, the presence of a mutation strongly corresponded with response to targeted therapy, but not to chemotherapy. Mutation-positive patients achieved a median survival of 3.6 years as compared with 1.6 years for mutation-negative patients.
This entry was posted on Monday, January 29th, 2007 at 9:34 am and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.